Biotechnology - Prosensa

Filter

Current filters:

Prosensa

Popular Filters

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Prosensa raises 23 million euros

26-01-2012

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases…

BiotechnologyFinancialProsensaRare diseasesResearch

Prosensa to get milestone payments from GSK under Duchenne collaboration

16-09-2011

Dutch biotech company Prosensa, focusing on rare diseases with an unmet medical need, has agreed with…

BiotechnologyFinancialGlaxoSmithKlineLicensingPharmaceuticalProsensaRare diseasesResearch

Back to top